Please assess the completion status of the following clinical trial:

Trial Title: A Study of MDX-1106 to Treat Patients With Hepatitis C Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Infection with hepatitis C genotype 1 or mixed hepatitis C genotype;~* Asymptomatic or nearly asymptomatic from hepatitis C;~* Previous therapy with interferon and ribavirin or peginterferon and ribavirin without an SVR or relapsed following an SVR;or Interferon naive subjects~* Chronically infected (at least 6 months since diagnosis) HCV-positive subjects;~* No evidence of bridging necrosis or cirrhosis;~* Liver biopsy within the last 2 years~Exclusion Criteria:~* Acute hepatitis C infection~* History of prior malignancy, acquired or inherited immunodeficiency or autoimmune disease either documented or anecdotal;

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).